Sermorelin & GHRP-6 & GHRP-2 Blend (9mg)

Sermorelin & GHRP-6 & GHRP-2 Blend (9mg) is a pre-weighed combination of complementary peptides in a single vial, synthesized and lyophilized in the USA.

Each vial of Sermorelin & GHRP-6 & GHRP-2 Blend (9mg) contains a pre-weighed ratio of Sermorelin 3mg, GHRP-6 3mg, GHRP-2 3mg in a single lyophilized cake, simplifying multi-peptide research protocols.

Sermorelin & GHRP-6 & GHRP-2 Blend (9mg) appears in dose-escalation designs that track tolerance and response stability across experimental groups.

Work with Sermorelin & GHRP-6 & GHRP-2 Blend (9mg) typically combines receptor-binding assays with LC-MS identity confirmation for batch consistency.

Sermorelin & GHRP-6 & GHRP-2 Blend (9mg) is studied within growth-hormone research for its influence on the somatotropic axis in experimental protocols.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Sermorelin & GHRP-6 & GHRP-2 Blend (9mg). Summaries are provided for orientation only and reflect the cited sources.

Treatment of growth-hormone deficiency with growth-hormone-releasing hormone^[1] — This clinical study evaluated treatment of growth-hormone deficiency with growth-hormone-releasing hormone in affected patients. The authors assessed growth and hormonal responses to GHRH administration. The findings suggested that GHRH therapy may be effective in stimulating growth in children with GH deficiency. (The Lancet 1987)

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency^[2] — This review summarized the use of sermorelin, the 1-29 fragment of growth hormone-releasing hormone, in the diagnosis and treatment of children with idiopathic growth hormone deficiency. The authors discussed the peptide's diagnostic utility and its therapeutic effects. The review indicated that sermorelin has a well-documented role in pediatric GH deficiency management. (BioDrugs 1999)

Development of growth hormone secretagogues^[3] — This review traced the discovery and development of growth hormone secretagogues, including GHRP-6 and related ligands of the ghrelin receptor. The author summarized how these compounds were identified and characterized as stimulators of GH release. The review provided a framework for understanding the GHRP class of peptides and their mechanism of action. (Endocrine Reviews 2005)

Growth hormone-releasing peptides^[4] — This review described the pharmacology and growth hormone-releasing activity of synthetic growth hormone-releasing peptides, such as GHRP-6. The authors summarized the endocrine responses elicited by these peptides in experimental and clinical settings. The review indicated that GHRPs represent a distinct class of GH secretagogues acting through the ghrelin receptor pathway. (European Journal of Endocrinology 1997)

Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women^[5] — This study examined the effects of a 30-day continuous subcutaneous infusion of GH-releasing peptide-2 (GHRP-2) on the growth hormone axis in older men and women. The authors measured pulsatile GH secretion as well as IGF-I, IGFBP-3, and IGFBP-5 concentrations throughout the infusion period. The results suggested that prolonged GHRP-2 administration sustains elevations of GH and related IGF markers in older adults. (The Journal of Clinical Endocrinology & Metabolism 2004)

Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption^[6] — This pharmacokinetic study evaluated ipamorelin and other peptidyl growth hormone secretagogues, with particular attention to their absorption after nasal administration. The authors compared the pharmacokinetic profiles of these peptides to assess their suitability for non-invasive delivery. The findings indicated that nasal absorption characteristics vary among the secretagogues examined. (Xenobiotica 1999)

References

1. Ross RJM, et al.. "Treatment of growth-hormone deficiency with growth-hormone-releasing hormone." The Lancet. 1987. pubmed.ncbi.nlm.nih.gov/2879138/
2. Prakash A, Goa KL. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency." BioDrugs. 1999. pubmed.ncbi.nlm.nih.gov/18031173/
3. Smith RG. "Development of growth hormone secretagogues." Endocrine Reviews. 2005. pubmed.ncbi.nlm.nih.gov/15814848/
4. Ghigo E, Arvat E, Muccioli G, Camanni F. "Growth hormone-releasing peptides." European Journal of Endocrinology. 1997. pubmed.ncbi.nlm.nih.gov/9186261/
5. Bowers CY, et al.. "Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women." The Journal of Clinical Endocrinology & Metabolism. 2004. academic.oup.com/jcem/article-pdf/89/5/2290/10743682/jcem2290.…
6. Johansen PB, Hansen KT, Andersen JV, Johansen NL. "Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption." Xenobiotica. 1999. pubmed.ncbi.nlm.nih.gov/9879640/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.